Innovations in Tablet Coating - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Innovations in Tablet Coating
Moderated by Angie Drakulich

Pharmaceutical Technology
Volume 35, pp. s18-s23

Uniformity of film-coating thickness is an important tablet quality attribute for a number of reasons. Poor uniformity or significant variability in film-coating thickness, can lead to a range of issues, depending on the purpose of the coating. In the case of coatings containing an active pharmaceutical ingredient (API), variability in potency between tablets arises directly from coating variability. For a functional coating governing the drug-release profile, variability in thickness can lead to variable drug-release profiles. Finally, high levels of variability for cosmetic coatings results in longer process times to ensure that all tablets have received a sufficient amount of coating.

In practice, obtaining uniform coating depends on good mixing of the tablets in the coating pan and a uniform distribution of tablet orientations in the spray zone to ensure uniform exposure of all sides of each tablet to the coating spray. The tablet-flow dynamics are governed by several factors, including the equipment geometry, the presence of any mixing elements (e.g., baffles), the conditions under which the equipment is operated, and the properties of the tablet cores, including size and shape. To fully explore the effects of each of these factors on film-coating uniformity necessitates a large number of physical experiments. Developing a model to study these effects in silico offers great savings in time, material, and labor costs.

DEM models are capable of accurately reproducing particle behavior in a number of pharmaceutical manufacturing processes and are growing in use throughout the industry (5). During the past few years, Pfizer has developed DEM models of various processes involving solid dosage forms using EDEM, a commercial DEM software package. Previous reports in the literature on film coating uniformity are limited to spherical, standard round convex (SRC), or oval tablet shapes, and are often focused on operating conditions rather than tablet shape (6–8). The computational approach reported here predicts both intertablet (i.e., uniformity between tablets) and intratablet (i.e., uniformity between surfaces of a given tablet) coating uniformity and allows for the study of many tablet shapes, including less common almond or bullet tablet shapes, permitting rapid screening of tablet shapes and operating conditions that ensure quality of tablet coating uniformity.

Figure 2 (Pfizer–DEM): Simulation image of bullet shaped tablets in a laboratory-scale film coating pan where intertablet coating variability is shown by varying degrees of blue color on each tablet, indicating the total residence time in the spray zone for a given tablet.
To investigate intertablet coating uniformity, EDEM simulations of the operation of pan coaters were carried out at various batch sizes, pan speeds, and different tablet shapes. The results were analyzed to determine the distributions of the residence time per pass through the spray zone for each tablet and the circulation time between successive appearances in the spray zone (see Figure 2). For conditions in which these distributions are wide, poor intertablet coating uniformity usually results. In a laboratory-scale coating pan, simulations predicted that the residence-time and circulation time variability both decrease with faster pan speeds. The effect of pan loading is mixed—residence time variability decreases with increasing loads but circulation time variability increases with increasing loads. The net effect in this case is an increase in variability for larger pan loads. Thus, improved intertablet coating uniformity is expected for faster pan speeds and smaller batch sizes, but consideration must also be given to maintaining reasonable process throughput, and the potential for increased tablet attrition that may occur at fast pan speeds.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here